Evidence map›Paper›PMID 33688910›Full record

ArticleJAMA dermatology2021

Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary.

John W Frew, Michelle Anne Lowes, Noah Goldfarb, Melissa Butt, Vincent Piguet, Elizabeth O'Brien, John Ingram, Gregor B E Jemec, Jerry Tan, Christos Zouboulis and 2 more

Open access · greenAbstract read
In one paragraph

Article in JAMA dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity.JID innovations : skin science from molecules to population health · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 5 countries.

John W FrewLaboratory of Investigative Dermatology, The Rockefeller University, New York City, New York.
Michelle Anne LowesThe Rockefeller University, New York City, New York.
Noah GoldfarbDepartment of Internal Medicine, University of Minnesota, Minneapolis.
Melissa ButtDepartment of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.
Vincent PiguetDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Elizabeth O'BrienDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
John IngramDepartment of Dermatology and Wound Healing, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom.
Gregor B E JemecDepartment of Dermatology, Zealand University Hospital, Roskilde, Denmark.
Jerry TanDepartment of Medicine, University of Western Ontario, Windsor, Ontario, Canada.
Christos ZouboulisDepartment of Dermatology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
Afsaneh AlaviDepartment of Dermatology, Mayo Clinic, Rochester, Minnesota.
Joslyn S KirbyDepartment of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.
Penn State Milton S. Hershey Medical Center · USRockefeller University · USCardiff University · GBMayo Clinic · USMedizinische Hochschule Brandenburg Theodor Fontane · DEUniversity of Minnesota · USUniversity of Toronto · CAWestern University · CAWomen's College Hospital · CAZealand University Hospital · DK

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
NCATS NIH HHS UL1 TR002014
6 · The paper itself

Abstract

Importance: Standard morphological terminology and definitions are vital for identification of lesion types in the clinical trial setting and communication about the condition. For hidradenitis suppurativa (HS), morphological definitions have been proposed by different groups, representing various regions of the world, but no international consensus has been reached regarding such definitions. A lack of globally harmonized terminology and definitions may contribute to poor-quality data collection in clinical trials as well as poor communication among clinicians, investigators, and patients. Objective: To establish and validate consensus definitions for typical morphological findings for HS lesions. Methods: This study was conducted from August 2019 to August 2020. A Delphi study technique was used to assess agreement and then resolve disagreement on HS terminology among international experts. After an initial preparation phase, the process consisted of 3 rounds. In each round, participants reviewed preliminary definitions and rated them as "keep, with no changes," "keep, with changes," or "remove." Eight HS primary lesions, including papule, pustule, nodule, plaque, ulcer, abscess, comedo, and tunnel, were selected because they are most frequently used in HS clinician-reported outcome measures. The initial definitions were based on extant literature, and modifications were made between rounds based on qualitative thematic analysis of open-ended responses or discussion. Consensus was defined as greater than 70% to accept a definition. Consensus stability across rounds was defined as less than 15% change in agreement. Reliability was evaluated using the Gwet agreement coefficient. Validation was based on assessment of face validity and stability across rounds. Results: A total of 31 experts participated. All 8 HS primary lesion definitions achieved greater than 70% consensus by Delphi round 3. Stability was achieved for papule, pustule, and abscess. The Gwet agreement coefficient increased from 0.49 (95% CI, 0.26-0.71) in round 1 to 0.78 (95% CI, 0.64-0.92) in round 3. Face validity was supported by expert endorsement to keep terms in survey responses. Previously unmeasured variation among clinicians' definition of tunnels was identified, and consensus was achieved. Conclusions and Relevance: An international group of experts agreed on definitions for morphological features of HS lesions frequently included in HS clinical trials. These international consensus terms and definitions are needed to support consistency of lesion identification and quantification in clinical trials.

Indexed as

ConsensusDelphi TechniqueDictionaries as TopicHidradenitis SuppurativaHumansInternationalityReproducibility of ResultsSurveys and QuestionnairesTerminology as Topic

Identifiers

PMID33688910
PMCPMC10448246
OpenAlexW3135490714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.